Bausch + Lomb Advances Two First-in-Class Eye Therapies After Promising Trial Results
Event summary
- Bausch + Lomb will advance its dual-action dry eye disease therapy into Phase 3 trials after Phase 2 results showed significant improvement in corneal staining at Day 15.
- The company's BL1332 ocular surface pain candidate met primary endpoints in a Phase 1b study, demonstrating significant pain reduction in a capsaicin-induced model.
- Estimated peak sales for the dual-action therapy are $700 million, while BL1332 could reach $1.4 billion if approved for multiple indications.
- Phase 2 results for BL1332 in post-surgical pain are expected within the next few months.
The big picture
Bausch + Lomb's advancements in first-in-class therapies position it to address significant unmet needs in eye health, particularly in dry eye disease and ocular surface pain. The company's dual-action approach and TRPV1 antagonist mechanism could reshape treatment paradigms, though success hinges on navigating regulatory hurdles and demonstrating sustained clinical benefits. With peak sales estimates exceeding $2 billion, these programs are critical to the company's long-term growth strategy beyond 2028.
What we're watching
- Regulatory Pathway
- Whether the Day 15 endpoint will be accepted by regulators for the dual-action therapy's Phase 3 trials.
- Market Potential
- The pace at which Bausch + Lomb can capture the estimated $2.1 billion peak sales opportunity from both therapies.
- Execution Risk
- How the company will balance development timelines for both programs while maintaining safety and efficacy profiles.